{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "12673465",
  "DateCompleted": {
    "Year": "2003",
    "Month": "10",
    "Day": "06"
  },
  "DateRevised": {
    "Year": "2018",
    "Month": "11",
    "Day": "13"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2003",
        "Month": "03",
        "Day": "01"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0941-4355",
      "JournalIssue": {
        "Volume": "11",
        "Issue": "4",
        "PubDate": {
          "Year": "2003",
          "Month": "Apr"
        }
      },
      "Title": "Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer",
      "ISOAbbreviation": "Support Care Cancer"
    },
    "ArticleTitle": "Cyclo-oxygenase II inhibitors in the treatment of neoplastic fever.",
    "Pagination": {
      "StartPage": "258",
      "EndPage": "259",
      "MedlinePgn": "258-9"
    },
    "Abstract": {
      "AbstractText": [
        "Neoplastic fever is relatively common in cancer patients. Naproxen is one of the most commonly used non-steroidal anti-inflammatory drugs for the treatment of neoplastic fever. Naproxen is associated with platelet dysfunction and gastrointestinal side effects. We substituted rofecoxib, a cyclooxygenase-II inhibitor, for naproxen in patients with a previous history of, or a newly diagnosed, neoplastic fever in whom naproxen was relatively contraindicated. In all patients the fever resolved completely without any side effects."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Department of Medicine, Wright State University, Dayton, Ohio, USA. satish@kathula.com"
          }
        ],
        "LastName": "Kathula",
        "ForeName": "Satheesh K",
        "Initials": "SK"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Shah",
        "ForeName": "Ketan",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Polenakovik",
        "ForeName": "Hari",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Koduri",
        "ForeName": "Jhansi",
        "Initials": "J"
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Germany",
    "MedlineTA": "Support Care Cancer",
    "NlmUniqueID": "9302957",
    "ISSNLinking": "0941-4355"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cyclooxygenase 2 Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Cyclooxygenase Inhibitors"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Isoenzymes"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Lactones"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Membrane Proteins"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Sulfones"
    },
    {
      "RegistryNumber": "0QTW8Z7MCR",
      "NameOfSubstance": "rofecoxib"
    },
    {
      "RegistryNumber": "EC 1.14.99.1",
      "NameOfSubstance": "Cyclooxygenase 2"
    },
    {
      "RegistryNumber": "EC 1.14.99.1",
      "NameOfSubstance": "PTGS2 protein, human"
    },
    {
      "RegistryNumber": "EC 1.14.99.1",
      "NameOfSubstance": "Prostaglandin-Endoperoxide Synthases"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Cyclooxygenase 2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Cyclooxygenase 2 Inhibitors"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Cyclooxygenase Inhibitors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Dose-Response Relationship, Drug"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Administration Schedule"
    },
    {
      "QualifierName": [
        "diagnosis",
        "drug therapy",
        "etiology"
      ],
      "DescriptorName": "Fever"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "antagonists & inhibitors"
      ],
      "DescriptorName": "Isoenzymes"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Lactones"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Membrane Proteins"
    },
    {
      "QualifierName": [
        "complications"
      ],
      "DescriptorName": "Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prostaglandin-Endoperoxide Synthases"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Sulfones"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}